Navigation Links
Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations
Date:11/4/2008

riod in 2007. Total business authorizations at Sept. 30, 2008, were $1.0 billion, an increase of 16 percent from Dec. 31, 2007, and an increase of 22 percent from Sept. 30, 2007. Contract cancellations for the third quarter 2008 totaled $38 million or 18 percent of gross sales for the quarter. The net book-to-bill ratio for the three months ended Sept. 30, 2008, was 1.4 to 1.

"Our impressive results for the quarter are a testament to the strength of our late stage markets, the value of our business model and the expertise and determination of our associates worldwide," said Chairman and CEO Candace Kendle, PharmD. "Coupled with our broad therapeutic and geographic reach, we believe we are well positioned to achieve our strategic growth initiatives and to meet our customers emerging outsourcing needs."

Income from operations for the three months ended Sept. 30, 2008, was $15.9 million, or 12.7 percent of net service revenues, compared to income from operations of $14.2 million, or 14.2 percent of net service revenues, for the same period of the prior year.

Cash flow from operations for the third quarter 2008 was $6.7 million compared with $13.7 million for the same period in 2007. Cash and marketable securities at Sept. 30, 2008, totaled $18.4 million, including $850,000 of restricted cash, compared with $29.1 million, which included $1.2 million of restricted cash at Sept. 30, 2007. In addition to the convertible notes that were outstanding at Sept. 30, 2008, the Company had $2.0 million of debt outstanding under its revolving credit facility. Days sales outstanding in accounts receivable were 46 days for the third quarter 2008 compared with 40 days for the same period of the prior year. Capital expenditures totaled $6.1 million compared with $3.4 million for the same period in 2007.

Nine-Month Results

Net income for the nine months ended Sept. 30, 2008, was $24.4 million or $1.63 on a diluted basis, an increase of 98 percent, comp
'/>"/>

SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Kendle Named to FORTUNE List of 100 Fastest-Growing Companies for 2008
2. Kendle to Present at the UBS Global Life Sciences Conference
3. Kendle Invites You to Attend its Second Quarter 2008 Earnings Conference Call and Webcast
4. Kendle to Host Conference Call and Webcast to Discuss DecisionLine Acquisition and Provide Update on Second Quarter Progress
5. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
6. Kendle Appoints Patricia Williams Vice President, Commercial Operations
7. Kendle Invites You to Attend its First Quarter 2008 Earnings Conference Call and Webcast
8. Kendle to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
9. Kendle Leaders Adopt 10b5-1 Trading Plans
10. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
11. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... RBJ today announces the firm brokered a long-term lease totaling ... biopharmaceutical company, at Two Ledgemont Center in Lexington, ... president, and Brian Cohen , senior vice president, represented ... 95 Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
(Date:1/22/2015)... laboratory information management systems market is a rapidly growing ... due to factors such as rising pressure to comply ... and increasing government support for adoption of HCIT solutions ... the market focus on technological advancements to further the ...
(Date:1/22/2015)... January 22, 2015 zFlo Motion , ... to announce an exciting product from a new partner. ... solutions over the past 15 years, with offerings in the ... their 3D IMU system (inertial measurement unit), iSen, is opening ...
(Date:1/22/2015)... 22, 2015 Diagenode, Inc., a ... the Bioruptor® and complete solutions for epigenetics research, ... immunoprecipitation, alleviating the need for manual processing. The ... for ChIP of histones or transcription factors and ...
Breaking Biology Technology:Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 43D Motion Capture Just Got Easy 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2
... the Sale of Ready to Drink,Suite of Nutritional Supplements to Provider ... ... BASKING RIDGE, N.J., June 5 Millennium Biotechnologies,Inc., wholly owned subsidiary ... it has entered into an,amendment of it,s November 9th 2007 Master ...
... Compendia Bioscience today,announced that it has signed ... GSK ) for Oncomine(TM) Enterprise Edition, a,value-added ... Edition builds upon the features of Oncomine,Professional ... to securely,view proprietary gene expression data in ...
... LAWRENCE, Mass., June 5 NxStage Medical, Inc.,(Nasdaq: ... announced that Jeffrey H. Burbank, Chief Executive Officer, and,Robert ... the William,Blair 28th Annual Growth Stock Conference on June ... NxStage,s investor presentation is scheduled for Wednesday, June ...
Cached Biology Technology:Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc. 2Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc. 3GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience 2NxStage Medical to Present at William Blair Growth Stock Conference 2
(Date:1/22/2015)... Inc. , a market leader of iris-based identity authentication solutions, ... the new role of Senior Vice President of Mobile and ... platforms and wearable solutions for EyeLock,s technologies. Gerber brings more ... industry to his role at EyeLock, with expertise in human ...
(Date:12/22/2014)... 2014 Holiday Season may be the brightest ever for ... the long anticipated floodgates for consumer biometrics may finally ... phones, tablets, and wearable mobile devices that incorporate biometrics ... with nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/17/2014)... DUBLIN , Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home Button ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... the iPhone 5S, Samsung introduces for the first time ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... multiple sclerosis (MS), neuroradiologists and neurologists of the University ... visualize inflammatory tissue damage, most of which had remained ... new contrast medium, Gadofluorine M, in magnetic resonance imaging. ... edition of the renowned medical journal Brain . ...
... About 4,000 children in the United States die every ... septic shock, and researchers are pushing the boundaries of ... the condition. But a simple measure of an immune ... the hospital for septic shock can predict survival in ...
... a pilot study in children with sarcoma, researchers at ... could prove beneficial in treating high-risk forms of this ... vaccine as well as a standard flu vaccine to ... findings, published in the August 1 issue of ...
Cached Biology News:Multiple Sclerosis: new MRI contrast medium enables early diagnosis in animal model 2Immune system protein accurate predictor of survival in pediatric septic shock 2Immune system protein accurate predictor of survival in pediatric septic shock 3Immunotherapy in high-risk pediatric sarcomas shows promising response 2Immunotherapy in high-risk pediatric sarcomas shows promising response 3
... are cytopathic effect inhibition assays, also known as ... tissue culture supernatents; serum from PK studies and ... is defined as the quantity of interferon required ... viral infection by 50%. All standards ...
... cytopathic effect inhibition assays, also known as CPE ... culture supernatents; serum from PK studies and delivery ... defined as the quantity of interferon required per ... infection by 50%. All standards used ...
Request Info...
Request Info...
Biology Products: